## Review setup
- **Input scope** Full manuscript text (abstract, introduction, methods, results, discussion, conclusions) as provided
- **Assessment boundary** Scientific content, methodological rigor, evidence quality, and internal consistency of the reported findings
- **Shared manuscript claim summary** The authors report nine distinct PAX2 variants in 10 pediatric patients, five of which are novel. They use AlphaFold 3 structural modeling and HK-2 cell proliferation assays to assess functional impact of four novel variants, and report two potential novel extrarenal phenotypes (hepatic dysfunction and spermatic cord hydrocele).
- **Visible evidence base** Clinical data from 10 patients (Table 2), genetic variant information (Table 3, Figure 1), AF3 structural predictions with RMSD values (Figure 2), Western blot and RT-qPCR data (Figure 3A–D), cell proliferation curves (Figure 3E,F)
- **Missing materials affecting confidence** Supplementary Table 1 (referenced but not provided), full Western blot images, raw cell counting data, primer sequences (Table 1 referenced but not provided), detailed clinical laboratory values, ophthalmological assessment details, liver biopsy histology images, statistical output details

## Reviewer
- **Overall assessment** This manuscript presents a clinically relevant case series of PAX2-related kidney disease in a pediatric Chinese cohort, with the identification of five novel variants. The combination of clinical phenotyping, structural prediction, and in vitro functional validation is commendable. However, several methodological limitations and interpretive overreach weaken the strength of the conclusions. The functional assays are limited to a single cell line and a single readout (proliferation), and the structural predictions from AlphaFold 3 are presented without experimental validation. The claim of novel phenotypes (hepatic dysfunction, hydrocele) is based on single cases without robust exclusion of alternative etiologies. The genotype-phenotype correlation analysis is descriptive rather than analytical, and the small sample size precludes meaningful statistical inference. The manuscript would benefit from more rigorous functional validation, clearer presentation of structural data, and more cautious interpretation of novel phenotype associations.

- **Who would be interested in the results, and why** Pediatric nephrologists and clinical geneticists would find this case series useful for expanding the known mutational and phenotypic spectrum of PAX2-related disorders, particularly in the Chinese population. Researchers studying kidney development and PAX2 function may be interested in the structural predictions and proliferation data. However, the limited functional depth and small cohort size reduce the broader impact for basic science audiences.

- **Major strengths** 
  1. Identification of five novel PAX2 variants, expanding the mutational spectrum in an understudied population
  2. Integration of clinical phenotyping with structural prediction and in vitro functional validation
  3. Detailed clinical characterization including renal biopsy data and extrarenal manifestations
  4. Clear documentation of ESKD progression and transplantation outcomes
  5. Appropriate use of ACMG guidelines for variant classification

- **Major Concerns**

- **Concern ID** R1-M1
- **Severity** Major
- **Blocking** Yes
- **Axis** Functional validation adequacy
- **Claim pointer** "Functional assays demonstrated that four novel variants significantly impaired the proliferative capacity of HK-2 cells" and "we show that these variants impair cell proliferation, offering mechanistic insights into their pathogenic effects"
- **Evidence pointer** Figure 3A–F, Methods sections "Cell proliferation assay" and "Western blotting"
- **Concern** The functional validation is limited to a single cell line (HK-2) and a single assay type (proliferation). The authors do not assess other relevant PAX2 functions such as transcriptional activity, DNA binding, or apoptosis, despite PAX2's well-documented anti-apoptotic role. The proliferation assay methodology is described as simple cell counting at 0, 24, 48, and 72 h, which does not distinguish between effects on proliferation versus cell survival. Additionally, the authors state that the c.424_c.427delAAAGinsTTTCAGCAGCC variant was not functionally tested due to "unequivocal pathogenicity," yet this variant has the smallest RMSD (1.2 Å) and its exclusion from functional validation is a missed opportunity to strengthen the genotype-phenotype correlation.
- **Why it matters** The central mechanistic claim of the manuscript rests on the proliferation data. Without additional functional readouts (e.g., transcriptional reporter assays, apoptosis assays, DNA binding studies) and without testing all five novel variants, the conclusion that these variants impair PAX2 function through reduced proliferation is insufficiently supported. The single-cell-line approach also limits generalizability.
- **Resolution test** The authors should either (a) expand functional validation to include transcriptional activity assays (e.g., luciferase reporter under PAX2-responsive promoter), apoptosis assays, and ideally test all five novel variants, or (b) substantially temper the mechanistic claims and present the proliferation data as preliminary evidence requiring further validation.

- **Concern ID** R1-M2
- **Severity** Major
- **Blocking** Yes
- **Axis** Structural prediction interpretation
- **Claim pointer** "AF3 modeling revealed significant conformational disruptions in the novel variants, with root mean square deviation (RMSD) values ranging from 1.1 to 43.6 Å" and "Both extensive global misfolding and focal local disruptions in PAX2 structure, as predicted by AF3 and quantified by RMSD, provide a mechanistic explanation for the impaired proliferation observed"
- **Evidence pointer** Figure 2, Methods section "Prediction and structural analysis of mutant PAX2 proteins"
- **Concern** The interpretation of AlphaFold 3 predictions is problematic. First, AlphaFold 3 is primarily designed for predicting protein structures and protein-ligand complexes, not for assessing the impact of point mutations on protein stability or conformation. The use of global RMSD as a metric for mutation impact is not standard practice and can be misleading, as large RMSD values may reflect domain flexibility or prediction uncertainty rather than true pathogenic conformational changes. Second, the authors do not provide confidence metrics (e.g., pLDDT scores) for the predicted structures, which are essential for interpreting the reliability of the predictions. Third, the claim that RMSD values "provide a mechanistic explanation" is an overstatement, as computational predictions without experimental validation (e.g., circular dichroism, thermal stability assays, or X-ray crystallography) cannot establish mechanism.
- **Why it matters** The structural analysis is presented as a key piece of evidence supporting pathogenicity. If the structural predictions are not reliable or are misinterpreted, the mechanistic narrative weakens substantially. The RMSD range of 1.1–43.6 Å is extremely wide, and the authors do not explain why some variants show minimal global changes yet still impair function, while others show massive deviations.
- **Resolution test** The authors should (a) provide pLDDT confidence scores for all predicted structures, (b) discuss the limitations of using AlphaFold 3 for mutation impact assessment, (c) consider alternative computational approaches (e.g., molecular dynamics simulations, FoldX stability calculations), and (d) either provide experimental validation of structural changes or temper the mechanistic claims accordingly.

- **Concern ID** R1-M3
- **Severity** Major
- **Blocking** No
- **Axis** Novel phenotype claims
- **Claim pointer** "Hepatic dysfunction and spermatic cord hydrocele were reported as potential novel phenotypes" and "we report two novel phenotypes potentially associated with PAX2 mutations, including unilateral hydrocele and liver dysfunction (hepatic fibrosis), which have not been previously described"
- **Evidence pointer** Table 2, Results section "Extrarenal manifestations"
- **Concern** The claim of novel phenotypes is based on single cases (patient 8 for hepatic dysfunction, patient 5 for hydrocele). For patient 8, the authors report elevated transaminases and liver biopsy showing mild hepatic fibrosis, but they do not provide a thorough exclusion of other causes of liver disease (e.g., viral hepatitis, autoimmune hepatitis, Wilson disease, drug-induced liver injury, non-alcoholic fatty liver disease). While the authors state they "excluded common etiologies," the specific tests performed are not detailed. For patient 5, the hydrocele is a common pediatric finding that may be incidental. The authors themselves acknowledge this possibility in the Discussion, but the framing in the Results and Abstract is more assertive.
- **Why it matters** Expanding the phenotypic spectrum of a genetic disorder requires robust evidence, particularly when the phenotype is common in the general pediatric population (hydrocele) or has multiple alternative etiologies (hepatic dysfunction). Over-attribution of novel phenotypes to PAX2 mutations could lead to misdiagnosis or inappropriate genetic counseling.
- **Resolution test** The authors should (a) provide detailed information on the diagnostic workup for patient 8 to exclude alternative causes of liver disease, (b) present the hydrocele case with appropriate caution, and (c) consider whether these findings are better framed as "potential associations requiring further investigation" rather than "novel phenotypes."

- **Concern ID** R1-M4
- **Severity** Major
- **Blocking** No
- **Axis** Genotype-phenotype correlation rigor
- **Claim pointer** "This study aims to analyze the clinical manifestations and genetic characteristics of children with PAX2 mutations and to assess the functional impact of novel variants" and the title "Genotype-phenotype correlations"
- **Evidence pointer** Tables 2 and 3, Results sections
- **Concern** Despite the title and stated aim, the manuscript does not actually perform a genotype-phenotype correlation analysis. The authors describe clinical features and list variants, but there is no systematic comparison of phenotypes across different variant types, no statistical analysis of genotype-phenotype associations, and no discussion of whether specific variants correlate with specific clinical outcomes. The small sample size (n=10) with nine distinct variants means that each variant is represented by a single patient, making any correlation analysis impossible.
- **Why it matters** The title and stated aim promise a genotype-phenotype correlation analysis that is not delivered. This misrepresents the scope of the study and may mislead readers about the strength of the conclusions that can be drawn.
- **Resolution test** The authors should either (a) revise the title and framing to accurately reflect the descriptive nature of the study, or (b) if they wish to retain the genotype-phenotype correlation framing, they should acknowledge the limitations of the small sample size and the descriptive nature of the analysis, and avoid implying correlations that are not statistically supported.

- **Minor Comments**

- **Concern ID** R1-m1
- **Severity** Minor
- **Axis** Statistical reporting
- **Affected element** Cell proliferation assay results
- **Evidence pointer** Figure 3E,F, Methods section "Statistical analysis"
- **Issue** The authors state that "cell proliferation assays revealed that all four new mutations reduced PAX2's ability to promote cell proliferation" but do not report the statistical significance of these differences. The Methods section describes the use of one-way ANOVA with Tukey's post hoc test, but the Results do not provide F-statistics, p-values, or effect sizes for the proliferation data.
- **Required correction** Provide statistical details for the proliferation assay results, including p-values for each mutant compared to wild-type, and specify the number of independent experiments performed.

- **Concern ID** R1-m2
- **Severity** Minor
- **Axis** Data presentation
- **Affected element** Western blot quantification
- **Evidence pointer** Figure 3A, Methods section "Western blotting"
- **Issue** The Western blot data are presented as representative images without quantification. The authors state that PAX2 protein levels were reduced for c.335G>A and c.482del, but no densitometry data or statistical analysis are provided.
- **Required correction** Provide quantification of Western blot bands (e.g., normalized to loading control) with statistical analysis, or clearly state that the data are qualitative observations.

- **Concern ID** R1-m3
- **Severity** Minor
- **Axis** Clinical data completeness
- **Affected element** Table 2
- **Evidence pointer** Table 2, Results section "General information"
- **Issue** The clinical data presented in Table 2 are not fully described in the text. For example, the authors mention "renal biopsy" findings for patients 4, 6, and 7, but the biopsy details (e.g., number of glomeruli, degree of interstitial fibrosis) are not provided. Additionally, the specific ophthalmological findings for patients with ocular abnormalities are not detailed.
- **Required correction** Provide more complete clinical descriptions in the text or as supplementary material, including biopsy findings and ophthalmological examination details.

- **Concern ID** R1-m4
- **Severity** Minor
- **Axis** Literature context
- **Affected element** Discussion section
- **Evidence pointer** Discussion section
- **Issue** The Discussion would benefit from a more comprehensive comparison with previously reported PAX2 variants and phenotypes, particularly in Asian populations. The authors cite several studies but do not systematically compare their findings with the existing literature on PAX2 mutation frequencies, common variants, or phenotypic variability.
- **Required correction** Expand the Discussion to include a more thorough comparison with published PAX2 cohorts, highlighting similarities and differences in variant distribution and clinical presentations.

- **Concern ID** R1-m5
- **Severity** Minor
- **Axis** Methodological detail
- **Affected element** AlphaFold 3 methodology
- **Evidence pointer** Methods section "Prediction and structural analysis of mutant PAX2 proteins"
- **Issue** The AlphaFold 3 methodology is described briefly. The authors do not specify the version of AlphaFold 3 used, the input sequences, the number of models generated, or the selection criteria for the final model. Additionally, the RMSD calculation method (e.g., which atoms were aligned, which reference structure was used) is not described.
- **Required correction** Provide more detailed methodology for the AlphaFold 3 predictions, including software version, input parameters, and RMSD calculation details.

- **Concern ID** R1-m6
- **Severity** Minor
- **Axis** Language and clarity
- **Affected element** Abstract and Results
- **Evidence pointer** Abstract, Results section
- **Issue** The phrase "hepatic dysfunction and spermatic cord hydrocele were reported as potential novel phenotypes" in the Abstract is somewhat ambiguous. It is unclear whether these are phenotypes observed in the current cohort or previously reported in the literature.
- **Required correction** Clarify the wording to indicate that these are phenotypes observed in the current cohort that have not been previously associated with PAX2 mutations.

## Risk / unsupported claims
- The claim that AlphaFold 3 RMSD values "provide a mechanistic explanation" for impaired proliferation is unsupported, as computational predictions without experimental validation cannot establish mechanism.
- The claim of "novel phenotypes" (hepatic dysfunction, spermatic cord hydrocele) is based on single cases without comprehensive exclusion of alternative etiologies, making these associations uncertain.
- The title's promise of "genotype-phenotype correlations" is not fulfilled by the descriptive analysis presented.
- The statement that "four novel variants significantly impaired the proliferative capacity of HK-2 cells" is not fully supported by the data presented, as statistical details are missing and the assay is limited to a single cell line and readout.
- The pathogenicity classification of c.1230_1238del as "uncertain" is acknowledged, yet this variant is included in the functional validation and discussed as if pathogenic, creating an inconsistency.
- The claim that "early genetic diagnosis and timely kidney-protective interventions are essential to improve outcomes" is a reasonable clinical recommendation but is not directly supported by the data presented in this study.

## Assessment against Nature-style criteria
- **Originality**: Moderate. The identification of five novel PAX2 variants adds to the known mutational spectrum, but the approach (case series with functional validation) is not methodologically novel. The use of AlphaFold 3 for variant assessment is relatively recent but not groundbreaking.
- **Scientific importance**: Moderate. PAX2-related kidney disease is rare, and expanding the variant spectrum is clinically useful. However, the small cohort size and limited functional depth reduce the broader scientific impact.
- **Interdisciplinary readership**: Limited. The manuscript is primarily relevant to pediatric nephrologists, clinical geneticists, and researchers studying kidney development. The functional data are not deep enough to attract a broader cell biology or structural biology audience.
- **Technical soundness**: The clinical phenotyping appears careful, but the functional validation is limited in scope (single cell line, single assay type). The AlphaFold 3 analysis lacks confidence metrics and experimental validation. Statistical reporting is incomplete.
- **Readability for nonspecialists**: The manuscript is generally well-written and accessible, with clear descriptions of clinical findings. However, the structural biology and functional assay sections may be challenging for readers without specialized knowledge.

## Recommendation posture
**Currently not established from the provided evidence.** The manuscript presents a clinically valuable case series with novel variants, but the mechanistic claims are insufficiently supported by the functional and structural data. The genotype-phenotype correlation framing is not delivered, and the novel phenotype associations require more rigorous evidence. The manuscript would be suitable for a specialty clinical genetics or nephrology journal after substantial revision, but it does not meet the standards for a high-impact general journal.